A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan

In response to the vaccine shortage of yellow fever vaccine (YF-VAX) due to manufacturing delays, the unapproved 17D-204 YF-VAX was used as an investigator-initiated clinical trial in Japan. The vaccine was administered to 11 279 participants in 19 YF vaccination centres in Japan, and few serious ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazato, Yusuke, Terada, Mari, Ujiie, Mugen, Saito, Sho, Moriya, Akinari, Ando, Masao, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075058/
https://www.ncbi.nlm.nih.gov/pubmed/35640301
http://dx.doi.org/10.1093/jtm/taac070
_version_ 1785019842988867584
author Miyazato, Yusuke
Terada, Mari
Ujiie, Mugen
Saito, Sho
Moriya, Akinari
Ando, Masao
Ohmagari, Norio
author_facet Miyazato, Yusuke
Terada, Mari
Ujiie, Mugen
Saito, Sho
Moriya, Akinari
Ando, Masao
Ohmagari, Norio
author_sort Miyazato, Yusuke
collection PubMed
description In response to the vaccine shortage of yellow fever vaccine (YF-VAX) due to manufacturing delays, the unapproved 17D-204 YF-VAX was used as an investigator-initiated clinical trial in Japan. The vaccine was administered to 11 279 participants in 19 YF vaccination centres in Japan, and few serious adverse events were observed.
format Online
Article
Text
id pubmed-10075058
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-100750582023-04-06 A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan Miyazato, Yusuke Terada, Mari Ujiie, Mugen Saito, Sho Moriya, Akinari Ando, Masao Ohmagari, Norio J Travel Med Research Letter In response to the vaccine shortage of yellow fever vaccine (YF-VAX) due to manufacturing delays, the unapproved 17D-204 YF-VAX was used as an investigator-initiated clinical trial in Japan. The vaccine was administered to 11 279 participants in 19 YF vaccination centres in Japan, and few serious adverse events were observed. Oxford University Press 2022-05-28 /pmc/articles/PMC10075058/ /pubmed/35640301 http://dx.doi.org/10.1093/jtm/taac070 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of International Society of Travel Medicine. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Letter
Miyazato, Yusuke
Terada, Mari
Ujiie, Mugen
Saito, Sho
Moriya, Akinari
Ando, Masao
Ohmagari, Norio
A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan
title A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan
title_full A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan
title_fullStr A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan
title_full_unstemmed A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan
title_short A nationwide prospective cohort study on safety of the 17D-204 yellow fever vaccine during a vaccine shortage in Japan
title_sort nationwide prospective cohort study on safety of the 17d-204 yellow fever vaccine during a vaccine shortage in japan
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075058/
https://www.ncbi.nlm.nih.gov/pubmed/35640301
http://dx.doi.org/10.1093/jtm/taac070
work_keys_str_mv AT miyazatoyusuke anationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT teradamari anationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT ujiiemugen anationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT saitosho anationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT moriyaakinari anationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT andomasao anationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT ohmagarinorio anationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT miyazatoyusuke nationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT teradamari nationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT ujiiemugen nationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT saitosho nationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT moriyaakinari nationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT andomasao nationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan
AT ohmagarinorio nationwideprospectivecohortstudyonsafetyofthe17d204yellowfevervaccineduringavaccineshortageinjapan

Ejemplares similares